Targeting RANKL Prevents Bone Loss, Improves Muscle Function and Extends Lifespan in Progeroid Mice

Area of Science:

• Genetics and Molecular Biology
• Gerontology
• Pharmacology

Background:

• Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder causing premature aging and early death.
• HGPS affects mesenchymal tissues, leading to osteoporosis, muscle wasting, and cardiovascular disease.
• Current treatments for HGPS are limited.

Purpose of the Study:

• To investigate the efficacy of targeting RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand) as an antiresorptive strategy in HGPS.
• To evaluate the impact of RANKL inhibition on bone loss and other phenotypes in preclinical HGPS models.

Main Methods:

• Utilized Zmpste24-/- mouse models, a preclinical model for HGPS.
• Employed genetic approaches, including osteocyte-specific RANKL deletion.
• Applied translational approaches using a neutralizing antibody against RANKL.

Main Results:

• Osteocyte-specific RANKL deletion in Zmpste24-/- mice reversed bone loss in long bones and vertebrae.
• Mice showed improved grip strength and endurance capacity.
• RANKL inhibition, via antibody treatment, restored bone mass, reduced muscle fibrosis, and extended lifespan.

Conclusions:

• Targeting RANKL demonstrates significant benefits for both bone and non-bone related symptoms in HGPS models.
• RANKL inhibition presents a promising therapeutic avenue for treating Hutchinson-Gilford progeria syndrome.
• This study supports further exploration of RANKL-targeting therapies for HGPS treatment.